Optimization of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by combining in vivo experiments and mathematical modeling
| hal.structure.identifier | Modélisation Mathématique pour l'Oncologie [MONC] | |
| hal.structure.identifier | Institut de Mathématiques de Bordeaux [IMB] | |
| dc.contributor.author | BENZEKRY, Sébastien | |
| dc.date.accessioned | 2024-04-04T03:02:34Z | |
| dc.date.available | 2024-04-04T03:02:34Z | |
| dc.date.conference | 2018-07-09 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/192999 | |
| dc.description.abstractEn | Concomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study in NSCLC-bearing mice that combined mathematical modeling with experimental investigations. First, experiments demonstrated improved efficacy when using sequential vs. concomitant scheduling of bevacizumab and chemotherapy. Combining this data with a mathematical model of tumor growth under therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant scheduling, and prolonged survival (74 vs. 70 days). Alternate sequencing of 8 days failed in achieving a similar increase in efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful tool in the clinic to personally tailor regimen sequences. | |
| dc.language.iso | en | |
| dc.subject.en | Personalized oncology | |
| dc.subject.en | Experimental therapeutics | |
| dc.subject.en | Antiangiogenic drugs | |
| dc.subject.en | Nonlinear mixed-effects modeling | |
| dc.subject.en | Combinations | |
| dc.title.en | Optimization of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by combining in vivo experiments and mathematical modeling | |
| dc.type | Communication dans un congrès | |
| dc.subject.hal | Sciences du Vivant [q-bio]/Cancer | |
| dc.subject.hal | Informatique [cs]/Modélisation et simulation | |
| dc.subject.hal | Physique [physics]/Physique [physics]/Analyse de données, Statistiques et Probabilités [physics.data-an] | |
| dc.subject.hal | Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie | |
| dc.subject.hal | Statistiques [stat]/Applications [stat.AP] | |
| bordeaux.hal.laboratories | Institut de Mathématiques de Bordeaux (IMB) - UMR 5251 | * |
| bordeaux.institution | Université de Bordeaux | |
| bordeaux.institution | Bordeaux INP | |
| bordeaux.institution | CNRS | |
| bordeaux.conference.title | Mathematical perspectives in the biology and therapeutics of cancer | |
| bordeaux.country | FR | |
| bordeaux.conference.city | Marseille | |
| bordeaux.peerReviewed | non | |
| hal.identifier | hal-01969142 | |
| hal.version | 1 | |
| hal.invited | oui | |
| hal.proceedings | non | |
| hal.conference.end | 2018-07-13 | |
| hal.popular | non | |
| hal.audience | Internationale | |
| hal.origin.link | https://hal.archives-ouvertes.fr//hal-01969142v1 | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.au=BENZEKRY,%20S%C3%A9bastien&rft.genre=unknown |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||